Just know, there are over 100 rare cann-a-binoids out there. This could be only the start of something even bigger.
Read The Full Company Presentation Here.
-----
Right now, INM has several potential catalysts to be aware of. Here they are:
No. 1 INM Potential Catalyst - Research Firm Edison Group Provides Huge $6.00 Price Target
"Huge" might be an understatement here.
Edison group slapped a $6.00 price target on INM last month which provides this profile with a stunning 500+% potential upside from Wednesday's closing valuation.
On top of that, they have even given INM a "Bull" estimate target of $16.00.
Here's some highlights from the report:
Company description: A platform of rare cann-a-binoids
InMed Pharmaceuticals is a North American-based biopharmaceutical company focused on researching, developing and manufacturing cann--abinoids for the therapeutic market, and also recently entered the cann-a-binoid commercial sales segment through its BayMedica acquisition. Through its pharma program, it is developing a proprietary pipeline of cann-a-binoids to treat target diseases. Its lead program is INM-755, a tropical cream using CBN for treating EB, which is currently enrolling patients for Phase II trials. It is also developing INM-088 for glaucoma, which is in a preclinical stage, and InMed is preparing for a Food and Drug Administration (FDA) preinvestigational new drug meeting (pre-IND) in Q2 CY22.
In parallel with its pharma program, it is developing its own proprietary manufacturing program IntegraSyn, an enzymatic process that uses E. coli to individually manufacture each of the c 140 cann-a-binoids. INM is also focusing on scaling up the IntegraSyn process to larger batch sizes in advance of commercial scale production. Furthermore, its product library of rare cann-a-binoid analogs creates a commercialization opportunity, while BayMedica’s aptitude in chemical synthesis and yeast biosynthesis to manufacture cann-a-binoids complements InMed’s capabilities in using E. coli through its IntegraSyn manufacturing platform.
With its recent acquisition of BayMedica, InMed is evolving from a pure-play firm focused on pharma R&D to a more diversified one with commercial sales in the health and wellness market, and we now expect it to exhibit near-term revenue generation combined with the longer-term value of its pharma drug development programs.
Valuation: Base scenario at US$85m, or US$6.0 per share
We have considered three scenarios in our risk-adjusted net present value (NPV) analysis. Our base case company valuation is US$85m, or US$6.0 per basic share, while the bull and bear scenarios are US$16.0 per basic share (US$227m) and US$1.5 per basic share (US$21m), respectively, compared to the previous US$20.53 per basic share or US$290m. The change in valuation is primarily due to a reassessment of both the base-case market share for the biosynthesis platform and the INM-755 product, as well as more conservative pricing estimates. In our model, we evaluated three scenarios where InMed could achieve different portions of its addressable market if its biosynthesis process is successfully validated and scaled to commercial levels. We also considered the market penetration InMed’s EB treatment could achieve, as well as the sales growth of the health & wellness products and potential price pressures as competitors enter the market. Given the early stage of its proprietary pipeline, the majority of the valuation stems from its biosynthesis platform, which targets a sizable and growing market for rare cann-a-binoids, and its potential EB treatment (INM-755).
-----
No. 2 INM Potential Catalyst - Another Low Float Profile
According to the Yahoo Finance website, INM has a low float.
The website reports this profile to have approximately 14.25Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
-----
No. 3 INM Potential Catalyst - Company Expands Patent Portfolio And Advances Collaboration Agreement
InMed Expands Patent Portfolio with Novel Cann-a-binoid Analogs and Advances Collaboration Agreement with Leading Cann-a-binoid Research Expert
- Expands library of proprietary cann-a-binoid analogs for pharma R&D
- Research collaboration initiated to screen analogs for therapeutic uses
VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cann-a-binoids, is pleased to announce the publication of a patent application in North America for several cann-a-binoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing.
Entitled “Cann-a-binoid Analogs and Methods for their Preparation”, the patent application describes several new cann-a-binoid-related chemical compounds that have not been previously described. If granted, the broad patent application allows for the creation of several variations of novel cann-a-binoid compounds, producing a robust library of proprietary new chemical entities (‘NCEs’).
Scientists at BayMedica, LLC, InMed’s subsidiary in the US, designed and produced these cann-a-binoid analogs. These NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cann-a-binoid with modifications that may make them preferred candidates to treat specific diseases.
Eric Hsu, SVP, Pre-Clinical Research and Development for InMed commented; “We believe rare cann-a-binoids hold tremendous therapeutic potential that may address a number of unmet medical needs. This patent covers the selective modification of naturally occurring cann-a-binoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D."
...
Read the full article here.
-----
No. 4 INM Potential Catalyst - Commercialization Of CB-DV Product Could Provide Major Boost
InMed Commercializes Cann-a-bidivarin (CB-DV), Expanding its Rare Cann-a-binoid Portfolio for the Health and Wellness Sector
- Expands rare cann-a-binoid portfolio beyond current C-B-C and C-B-T
- Releases White Paper outlining research into the therapeutic potential of CB-DV
VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cann-a-binoids, is pleased to announce it has launched B2B sales of the rare cann-a-binoid cann-a-bidivarin (“CB-DV”) to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC.
“Ensuring a reliable, large volume source of highly pure, bioidentical CB-DV is an important step forward in the health and wellness sector. CB-DV has been researched for its therapeutic potential in several disease areas such as autism spectrum disorder,” said Shane Johnson, MD, SVP and General Manager of BayMedica. “Whether you are a researcher or product developer at a multinational consumer package goods (‘CPG’) company, the ability to access highly pure and consistent active ingredients, free from contaminants typically found in plant-sourced cann-a-binoids such as pesticides, heavy metals, or potentially even T-H-C, is a fundamental requirement. BayMedica’s cann-a-binoid manufacturing technologies provides exactly that value and we are excited to continue to introduce to the market additional rare cann-a-binoids that have previously not been abundantly accessible, including adding TH-CV to our portfolio in the immediate future.”
...
Read the full article here.
-----
Nasdaq Profile Recap - Top 4 INM Potential Catalysts
No. 1 - Research Firm Edison Group Provides Huge $20+ Price Target
No. 2 - Another Low Float Profile
No. 3 - Company Expands Patent Portfolio And Advances Collaboration Agreement
No. 4 - Commercialization Of CB-DV Product Could Provide Major Boost
-----
Coverage is officially initiated on INM. When you have time later, do this:
